215 related articles for article (PubMed ID: 26878194)
1. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
Benešová M; Bauder-Wüst U; Schäfer M; Klika KD; Mier W; Haberkorn U; Kopka K; Eder M
J Med Chem; 2016 Mar; 59(5):1761-75. PubMed ID: 26878194
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
3. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with
Greifenstein L; Engelbogen N; Lahnif H; Sinnes JP; Bergmann R; Bachmann M; Rösch F
ChemMedChem; 2020 Apr; 15(8):695-704. PubMed ID: 32057189
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Preclinical Evaluation of [
Bailey JJ; Wuest M; Wagner M; Bhardwaj A; Wängler C; Wängler B; Valliant JF; Schirrmacher R; Wuest F
J Med Chem; 2021 Nov; 64(21):15671-15689. PubMed ID: 34672630
[TBL] [Abstract][Full Text] [Related]
6. Radiochemistry and Preclinical PET Imaging of
Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
[TBL] [Abstract][Full Text] [Related]
7. Development of
Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
9. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Wang Z; Tian R; Niu G; Ma Y; Lang L; Szajek LP; Kiesewetter DO; Jacobson O; Chen X
Bioconjug Chem; 2018 Sep; 29(9):3213-3221. PubMed ID: 30105912
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
Banerjee SR; Pullambhatla M; Byun Y; Nimmagadda S; Green G; Fox JJ; Horti A; Mease RC; Pomper MG
J Med Chem; 2010 Jul; 53(14):5333-41. PubMed ID: 20568777
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Yao X; Zha Z; Ploessl K; Choi SR; Zhao R; Alexoff D; Zhu L; Kung HF
Bioorg Med Chem; 2020 Mar; 28(5):115319. PubMed ID: 32001090
[TBL] [Abstract][Full Text] [Related]
13. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of a novel near-infrared fluorescent probe based on succinimidyl-Cys-C(O)-Glu that targets prostate-specific membrane antigen for optical imaging.
Matsuoka D; Watanabe H; Shimizu Y; Kimura H; Ono M; Saji H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4876-4880. PubMed ID: 28964633
[TBL] [Abstract][Full Text] [Related]
15. PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties.
Garnuszek P; Karczmarczyk U; Maurin M; Sikora A; Zaborniak J; Pijarowska-Kruszyna J; Jaroń A; Wyczółkowska M; Wojdowska W; Pawlak D; Lipiński PFJ; Mikołajczak R
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800517
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates.
Lu G; Maresca KP; Hillier SM; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1557-63. PubMed ID: 23333070
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and preclinical evaluation of
Liu T; Liu C; Liu F; Xu X; Guo X; Xia L; Zhu H; Yang Z
Bioorg Med Chem Lett; 2019 Apr; 29(7):933-937. PubMed ID: 30745258
[TBL] [Abstract][Full Text] [Related]
19. Development and preliminary evaluation of an integrin α
Lu X; Wu M; Wang S; Hai W; Li P
Bioorg Med Chem; 2022 Jan; 54():116583. PubMed ID: 34952297
[TBL] [Abstract][Full Text] [Related]
20. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]